The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.
The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Vaccines Sales Market forecasts from 2019-2029
• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket: • Paediatric Vaccines • Adult Vaccines • Elderly Vaccines • Travel Vaccines • Therapeutic Vaccines
• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines: • Prevnar • Gardasil • Fluzone • Pentacel • ProQuad • Infanrix/Pediarix • Zostavax • RotaTeq • Hepatitis Vaccines • Menactra
• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market: • US • EU5: Germany, France, Italy, UK, Spain • Japan • Brazil • Russia • India • China
• Profiles of the selected leading companies: • AstraZeneca • Eli Lilly • Emergent BioSolutions Inc. • GlaxoSmithKline • Johnson & Johnson • Merck & Co. • Pfizer • Sanofi • Serum Indian Institute Pvt. Ltd. • Takeda
• The Vaccines Market Pipeline Analysis
• A SWOT and STEP analysis of the global vaccines market
• Key Questions Answered by this Report: • What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029? • What are the main drivers and restraints that will shape the overall vaccines market over the next ten years? • What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028? • How will political and regulatory forces influence regional markets? • How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029? • Who are the leading companies and what are their activities, results, developments and prospects? • What are the leading vaccines? What are their revenues and latest developments? • What are some of the most prominent human vaccines currently in development? • What are the main trends that will affect the world vaccines market between 2018 and 2029? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the social, technological, economic and political influences that will shape that industry over the next ten years? • How will the global vaccines market evolve over the forecasted period, 2018 to 2029? • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029? • Which therapies can succeed and what revenues could they generate to 2029? • What will be the main commercial drivers for the market from 2018 to 2029? • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth? • How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines - Aiming for Global Disease Prevention
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
